Physician profile
Igor Nedic
NPI 1316913304
$1,822.34
in general payments reported to CMS, 2019-2025
26 companies · $332 in 2025
The $332 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $324 · 2020: $69.02 · 2021: $227 · 2022: $315 · 2023: $310 · 2024: $246 · 2025: $332.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $888.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $888.09 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $606.51 | 2021-2024 | |
| Amgen INC. | $171.41 | 2019-2025 | Evenity, Prolia, Repatha |
| Janssen Pharmaceuticals, INC | $164.11 | 2019-2022 | |
| Glaxosmithkline, LLC. | $146.79 | 2020-2025 | Trelegy Ellipta |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $123.47 | 2025 | Caplyta |
| Novartis Pharmaceuticals Corporation | $62.71 | 2019-2022 | |
| Novo Nordisk INC | $61.87 | 2021-2025 | Wegovy, Ozempic, Rybelsus |
| Allergan, INC. | $54.95 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $53.39 | 2022-2025 | Xifaxan |
| Astellas Pharma US INC | $48.55 | 2025 | Veozah |
| Qol Medical, LLC | $37.91 | 2023 | Sucraid |
| Boehringer Ingelheim Pharmaceuticals, INC. | $32.86 | 2023-2024 | Jardiance, Ofev |
| Alkermes, INC. | $29.49 | 2025 | Vivitrol |
| Ani Pharmaceuticals, INC. | $25.00 | 2025 | Purified Cortrophin Gel |
| Vanda Pharmaceuticals INC. | $22.81 | 2021 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic Minimed, INC. | $22.12 | 2019 | |
| Valeritas, INC. | $21.04 | 2019 | |
| Exact Sciences Corporation | $20.42 | 2023 | Cologuard Collection Kit |
| Paratek Pharmaceuticals, INC. | $17.67 | 2022 | |
| Lundbeck LLC | $16.60 | 2023 | Rexulti |
| Merck Sharp & Dohme LLC | $16.60 | 2021 | |
| Seqirus USA INC | $16.51 | 2024 | Fluad, Flucelvax |
| Medtronic, INC. | $13.77 | 2022 | |
| Eisai INC. | $12.22 | 2019 | |
| Astrazeneca Pharmaceuticals Lp | $11.80 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $11.76 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Igor Nedic listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.